With Positive Study Results, Genomic Health on Track to Launch Oncotype DX Prostate Cancer in 2013
September 19, 2012
With Positive Study Results, Genomic Health on Track to Launch Oncotype DX Prostate Cancer in 2013
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Prostate Cancer MDx Competition Heating Up; New Data from Genomic Health, Myriad
May 15, 2013 / Pharmacogenomics Reporter - With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter - Wall Street Closely Tracking Validation Data on Genomic Health's Oncotype DX Prostate Cancer Test
April 3, 2013 / Pharmacogenomics Reporter - After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter - Genomic Health Attributes Q3 Revenue Growth to Strong International Test Adoption
November 14, 2012 / Pharmacogenomics Reporter